Hyperlipidemia and hypothyroidism

X, Su; Peng, Hua; Chen, Xiang; Wu, Xi-Jie; Wang, Bin

doi:10.1016/j.cca.2022.01.006

Cited by 66 publications

(40 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subclinical hypothyroidism (SCH) is an endocrine and metabolic disorder that is characterized by elevated serum thyroid-stimulating hormone (TSH) above the upper limit of reference with normal serum free thyroid hormones (FT4 and FT3) ( 1 ). Recently, several studies have shown that SCH is associated with hypercoagulability ( 2 ), cardiovascular disease ( 3 ), dyslipidaemia ( 4 ), and increased carotid artery atherosclerosis ( 5 ). Atherosclerosis is a chronic inflammatory response with a complex pathological mechanism.…”

Section: Introductionmentioning

confidence: 99%

Expression patterns of serum MicroRNAs related to endothelial dysfunction in patients with subclinical hypothyroidism

Yao

Wang

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundIncreasing evidence has shown that elevated Thyroid stimulating hormone (TSH) levels are positively correlated with atherosclerosis (ATH) in patients with subclinical hypothyroidism (SCH). Some researchers found that the dysfunction of Endothelial Cells (ECs) in SCH plays an important role in the pathogenesis of ATH in SCH, but the association remains controversial.ObjectivesTo determine the expression profiles of serum microRNAs critical to the function of Endothelial cells (ECs) may help reanalyze the possible mechanism underlying ATH in SCH and the association between ATH and SCH.MethodsWe used qRT-PCR to perform microRNA profiling and analysis in normal control subjects (NC), patients with SCH alone (SCH), patients with SCH and ATH (SCH+ATH), and patients with ATH without SCH (ATH).ResultsBoth miR-221-3p and miR-222-3p showed a decreasing expression trend between the SCH and SCH+ATH groups. In addition, miR-126-3p and miR-150-5p showed a stepwise decrease from the NC to SCH groups and then to the SCH+ATH or ATH group. miR-21-5p was unregulated in the SCH, SCH+ATH, and ATH groups. Furthermore, elevated levels of miR-21-5p in SCH+ATH group were higher than SCH and ATH group. No differences were found in the levels of miR-150, miR-126, miR-221 and miR-222 between the ATH and the SCH+ATH subjects.ConclusionsmiR-21-5p may be involved in the atherosclerosis process in patients with SCH (SCH and SCH+ATH groups). miR-150-5p may be sensitive risk markers for predicting endothelial dysfunction in patients with ATH (ATH and SCH+ATH groups).

show abstract

Section: Introductionmentioning

confidence: 99%

Expression patterns of serum MicroRNAs related to endothelial dysfunction in patients with subclinical hypothyroidism

Yao

Wang

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…В большинстве случаев врачи различных специальностей (кардиологи, неврологи, участковые терапевты, врачи общей практики) сталкиваются и анализируют уже клинические кардиальные и церебральные исходы и осложнения у пациентов с патологией щитовидной железы, часто рассматривая эндокринную патологию в качестве сопутствующего, но не потенцирующего атерогенез состояния. В отношении стратификации групп кардиоваскулярного и церебрального риска, необходимости выбора сроков начала и способов антиатерогенной терапии у пациентов с различным гормональным статусом щитовидной железы мнения ученых весьма противоречивы [14,[29][30][31][32][33][34][35][36][37][38][39]. Кроме того, в случае подозрения на вторичную гиперлипидемию необходимо учитывать и другие обстоятельства, обусловленные коморбидностью патологии.…”

Section:  вторичная гиперлипидемия и атеросклероз у пациентов с пато...unclassified

Secondary Hyperlipidemia and Atherosclerosis in Patients with Thyroid Pathology

Петрова¹,

N.²,

Т.В.³

et al. 2023

Кардиология В Беларуси

View full text Add to dashboard Cite

Несмотря на достижения отечественного и зарубежного здравоохранения, патология сердечно-сосудистой системы (ССС), ассоциированная с атеросклерозом, вносит существенный вклад в статистику общей смертности в Европе и Республике Беларусь. Жизнеугрожающие осложнения со стороны ССС, трактуемые как кардиоваскулярные риски, и их предупреждение находятся в фокусе приоритетных направлений мирового здравоохранения. Каждый второй представитель развитых стран в возрасте 40 лет и старше погибает от последствий атеросклероза. Ранняя инвалидизация и высокая смертность пациентов трудоспособного возраста, масштабы финансовых затрат на этапах амбулаторного и стационарного лечения, потребность рационального использования средств бюджета стран на реабилитацию, в том числе льготное обеспечение данной категории лиц, проведение дорогостоящих интервенционных и кардиохирургических лечебно-диагностических процедур наглядно демонстрируют необходимость поиска новых научно обоснованных основ стратификации групп кардиоваскулярного риска и профилактических подходов. Неослабевающий научный и практический интерес представляет изучение вклада коморбидных состояний в механизмы развития вторичной гиперлипидемии и атерогенеза. На сегодняшний день, по данным Всемирной организации здравоохранения, поражение щитовидной железы занимает второе место в перечне эндокринных заболеваний после нарушения обмена углеводов. Гиперлипидемия у пациентов с нарушением функции щитовидной железы (гипо- или гипертиреоз) является сложной мультидисциплинарной проблемой, требующей углубленного изучения. В настоящем обзоре представлено современное видение проблемы, отражены основные вопросы метаболизма тиреоидных гормонов, их роль в развитии дислипидемии и структурно-функционального поражения миокарда, новые взгляды на профилактику кардиоваскулярных рисков у пациентов с дисфункцией щитовидной железы. Despite the achievements of national and foreign health care, atherosclerosis-related cardiovascular diseases (CVD) contribute significantly to the total mortality in Europe and the Republic of Belarus. Life-threatening complications of CVD, interpreted as cardiovascular risks, and their prevention are in the focus of the global health care priorities. Every second inhabitant of developed countries aged 40 years and older dies due to atherosclerosis outcomes. Early disability and high mortality of patients of working age, extent of financial costs at outpatient and inpatient stages of treatment, needs for rational use of national budgets funds for rehabilitation, including preferential provision for this category of people, expensive interventional and cardiac surgery treatment and diagnostic procedures, clearly demonstrate the necessity of searching for a new evidence- based stratification of cardiovascular risk groups and preventive approaches. The contribution of comorbid conditions in the mechanisms of secondary hyperlipidemia and atherogenesis development is of ongoing scientific and clinical interest. According to the World Health Organization, thyroid gland involvement occupies the second place in the list of endocrine diseases after carbohydrate metabolism disorders. Dyslipidemia in patients with thyroid dysfunction (hypo- or hyperthyroidism) is a complex multidisciplinary problem that requires extensive study. This review presents the current view of the problem, reflects the main issues of thyroid hormones metabolism, in development of dyslipidemia and structural and functional myocardial involvement, and current views on prevention of cardiovascular risks in patients with thyroid dysfunction.

show abstract

“…27 Fatigue and weight gain can reduce physical activity, adding to glucose variability. In addition, untreated hypothyroidism leads to an adverse lipid profile with increased total and low density lipoprotein cholesterol as well as triglycerides and dysfunctional high density lipoprotein cholesterol 28 thus increasing the risk of cardiovascular disease. Furthermore, hypothyroidism is associated with changes in vascular endothelial growth factor that increases the risk of diabetic retinopathy.…”

Section: T1dm and Hashimoto's Diseasementioning

confidence: 99%

The challenges of managing type 1 diabetes with other autoimmune diseases

Salloum

Poole

2022

Practical Diabetes

View full text Add to dashboard Cite

People with type 1 diabetes have an increased risk of developing other autoimmune diseases compared to the background population and this risk has been increasing over the last 20 years. Coeliac disease affects absorption of food which can lead to hypoglycaemia in people with diabetes. Both conditions have dietary restrictions and managing the two can make food choices more difficult. Addison's disease can lead to significant challenges in managing blood glucose particularly in times of intercurrent illness and significantly increases morbidity and mortality in patients with diabetes. Thyroid disease, both hyperthyroidism (Graves’ disease) and hypothyroidism (Hashimoto's thyroiditis) can affect blood glucose levels directly by changes in glucose uptake and metabolism or indirectly through changes in weight. Management of type 1 diabetes includes being alert to the possibility of these potential additional diagnoses. Copyright © 2022 John Wiley & Sons.

show abstract

Hyperlipidemia and hypothyroidism

Cited by 66 publications

References 110 publications

Expression patterns of serum MicroRNAs related to endothelial dysfunction in patients with subclinical hypothyroidism

Expression patterns of serum MicroRNAs related to endothelial dysfunction in patients with subclinical hypothyroidism

Secondary Hyperlipidemia and Atherosclerosis in Patients with Thyroid Pathology

The challenges of managing type 1 diabetes with other autoimmune diseases

Contact Info

Product

Resources

About